Cancer BiologybioRxivPreprint
A Novel Drug Candidate that Selectively Targets the Critical Androgen Receptor-ELK1 Growth Axis in Advanced and Drug-Resistant Prostate Cancer
Claire L. Soave, Lisa Polin, Charles E. Ducker…·Manohar Ratnam
This paper develops a new compound KCI838 that selectively inhibits the AR-ELK1 axis in prostate cancer, showing potent anti-tumor activity in resistant models.
DOI 10.64898/2026.05.26.727474